Manufacturer of Controlled Substances; Notice of Application, 7924 [E9-3646]
Download as PDF
<![CDATA[
7924
Federal Register / Vol. 74, No. 33 / Friday, February 20, 2009 / Notices
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Oxycodone (9143) .........................
Morphine (9300) ............................
II
II
Drug
The company plans to import
controlled substances for clinical trials
and analytical testing.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 23, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: February 13, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–3650 Filed 2–19–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 8, 2009,
Sigma Aldrich Research Biochemicals,
Inc., 1–3 Strathmore Road, Natick,
VerDate Nov<24>2008
17:55 Feb 19, 2009
Jkt 217001
Massachusetts 01760–2447, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ...................
Aminorex (1585) ............................
Gamma
Hydroxybutyric
Acid
(2010).
Alpha-ethyltryptamine (7249) ........
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) ......
4–Bromo-2,5dimethoxyamphetamine (7391).
4–Bromo-2,5dimethoxyphenethylamine
(7392).
2,5–Dimethoxyamphetamine
(7396).
3,4–Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4–Methylenedioxy-Nethylamphetamine (7404).
3,4–
Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ...........................
5–Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2–
Thienyl)cyclohexyl]piperidine
(TCP) (7470).
1–Benzylpiperazine (BZP) (7493)
Heroin (9200) ................................
Normorphine (9313) ......................
Amphetamine (1100) .....................
Methamphetamine (1105) .............
Nabilone (7379) .............................
1–Phenylcyclohexylamine (7460)
Phencyclidine (7471) .....................
Cocaine (9041) ..............................
Codeine (9050) .............................
Diprenorphine (9058) ....................
Ecgonine (9180) ............................
Levomethorphan (9210) ................
Levorphanol (9220) .......................
Meperidine (9230) .........................
Metazocine (9240) ........................
Methadone (9250) .........................
Morphine (9300) ............................
Thebaine (9333) ............................
Levo-alphacetylmethadol (9648) ...
Carfentanil (9743) .........................
Fentanyl (9801) .............................
I
I
I
I
I
I
I
I
Frm 00075
Fmt 4703
Sfmt 4703
Dated: February 13, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–3646 Filed 2–19–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
I
Manufacturer of Controlled
Substances; Notice of Registration
I
By Notice dated October 28, 2008 and
published in the Federal Register on
November 3, 2008, (73 FR 65404),
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
reference standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
PO 00000
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 21, 2009.
Drug
Tetrahydrocannabinols (7370) ......
Dihydromorphine (9145) ...............
Dihydrocodeine (9120) ..................
Oxycodone (9143) .........................
Hydromorphone (9150) .................
Hydrocodone (9193) .....................
Remifentanil (9739) .......................
Sufentanil (9740) ...........................
Fentanyl (9801) .............................
Schedule
I
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
E:\FR\FM\20FEN1.SGM
20FEN1
]]>Agencies
[Federal Register Volume 74, Number 33 (Friday, February 20, 2009)]
[Notices]
[Page 7924]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-3646]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 8, 2009, Sigma
Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick,
Massachusetts 01760-2447, made application by renewal to the Drug
Enforcement Administration (DEA) as a bulk manufacturer of the basic
classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)............................ I
Methcathinone (1237)........................ I
Aminorex (1585)............................. I
Gamma Hydroxybutyric Acid (2010)............ I
Alpha-ethyltryptamine (7249)................ I
Lysergic acid diethylamide (7315)........... I
Tetrahydrocannabinols (7370)................ I
4-Bromo-2,5-dimethoxyamphetamine (7391)..... I
4-Bromo-2,5-dimethoxyphenethylamine (7392).. I
2,5-Dimethoxyamphetamine (7396)............. I
3,4-Methylenedioxyamphetamine (7400)........ I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine (7404) I
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
Psilocybin (7437)........................... I
5-Methoxy-N,N-diisopropyltryptamine (7439).. I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) I
(7470).
1-Benzylpiperazine (BZP) (7493)............. I
Heroin (9200)............................... I
Normorphine (9313).......................... I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
Nabilone (7379)............................. II
1-Phenylcyclohexylamine (7460).............. II
Phencyclidine (7471)........................ II
Cocaine (9041).............................. II
Codeine (9050).............................. II
Diprenorphine (9058)........................ II
Ecgonine (9180)............................. II
Levomethorphan (9210)....................... II
Levorphanol (9220).......................... II
Meperidine (9230)........................... II
Metazocine (9240)........................... II
Methadone (9250)............................ II
Morphine (9300)............................. II
Thebaine (9333)............................. II
Levo-alphacetylmethadol (9648).............. II
Carfentanil (9743).......................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 21, 2009.
Dated: February 13, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-3646 Filed 2-19-09; 8:45 am]
BILLING CODE 4410-09-P
